Is the «equivalent chlorpromazine» dose in psychopharmacotherapy consistent with Good Clinical Practice?
Abstract
Principles of adequate pharmacotherapy in psychiatry imply that shifting from one antipsychotic to another requires recalculation of the effective dose using the «chlorpromazine equivalent». The latter is deemed a reference measure for finding equally effective doses among antipsychotics. Given the molecular masses of the active substances and recommended drug doses, the association between the potential antipsychotic efficacy and the «complexity» of the molecules is analyzed in the present study. It is shown that the treatment efficacy is connected with the number of the substance molecules consumed with the certain drug dose. The lack of difference between «selective» and «non-selective» antipsychotics regarding association of their molecular masses and respective clinical activity challenges the suitability of the «chlorpromazine equivalent» for calculating antipsychotic doses. We assume that the approach based on the proportional ratio utilizing the highest drug dose recommended by the manufacturer is more adequate method of the antipsychotic dose estimation.
About the Authors
M. Yu. Popov
V.M. Bekhterev psychoneurological research institute
Russian Federation
Russian Federation
P. V. Kozlovskaya
I.P Pavlov first state medical university
Russian Federation
Russian Federation
References
1. Козловский В.Л. Лекарственная резистентность в психиатрии - проблема патофизиологии или фармакологии? // Журнал неврологии и психиатрии им. С.С. Корсакова. - 2009. - № 1. - С. 86-90.
2. Мосолов С.Н., Алфимов П.В. Роль дофаминовых D3-рецеnторов в механизме действия современных антипсихотиков // Современная терапия психических расстройств. - 2014. - № 1. - С. 2-9.
3. Попов М.Ю. Фармакотерапия шизофрении: анализ объективных трудностей // Российский психиатрический журнал. - 2003. - № 4. - С. 41-45.
4. Прозоровский В.Б., Прозоровская М.П., Демуренко В.М. Экспресс-метод определения средней эффективной дозы и ее ошибки // Фармакология и токсикология. - 1978. - Т. 41, № 4. - С. 497-502.
5. Снедков Е.В. Мифы об антипсихотиках // Проблемы и перспективы развития стационарной психиатрической помощи (в 2-х т.) / Под ред. О.В. Лиманкина. - СПб. - 2009. - Том 1. - C 440-448.
6. Стандарты оказания помощи больным шизофренией / Под ред. В.Н. Краснова, И.Я. Гу-ровича, С.Н. Мосолова, А.Б. Шмуклера. - М.: Московский НИИ психиатрии. - 2006. - 268 с.
7. Федеральное руководство по использованию лекарственных средств (формулярная система). Вып. XIV / Под ред. А.Г. Чучалина, Ю.Б. Белоусова, С.П. Голицина и др. - М.: ЗАО РИЦ «Человек и лекарство». - 2013. - 995 с.
8. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia // Am. J. Psychiatry. - 1997. - Vol. 154, Suppl. 4. - P. 1-6.
9. Andreasen N.C., Pressler M., Nopoulos P. et al. Antipsychotic dose equivalents and dose-years: A standardized method for comparing exposure to different drugs // Biol. Psychiatry. - 2010. - Vol. 67. - P. 255-262.
10. Arnt J., Skarsfeld T. Do novel antipsychotics have similar pharmacological characteristics? A Review of the evidence // Neuropsychopharmacology. - 19 98. - Vol. 18. - P. 63-101.
11. Bennet M.R. Monoaminergic synapses and schizophrenia: 45 years of neuroleptics // J. Psychopharmacol. - 1998. - Vol. 12. - P. 289-304.
12. Clark M.L., Ramsey H.R., Ragland R.E. et al. Chlorpromazine in chronic schizophrenia: behavioral dose-response relationships // Psychoph armacologia. - 1970. - Vol. 18. - P. 260-270
13. Davis J.M. Dose equivalence of the antipsychotic drugs // J. Psychiatr. Res. - 1974. - Vol. 11. - P. 65-69.
14. Garry J.W., Leonard T.J. Haloperidol: a controlled trial in chronic schizophrenia // J. Ment. Sci. - 1962. - Vol. 108. - P. 105-107.
15. Grygier P., Waters M.A. Chlorpromazine used with an intensive occupational therapy program; a controlled study // AMA Arch. Neurol. Psychiatry. - 1958. - Vol. 79. - P. 697-705.
16. McEvoy J.P., Scheifler P.L., Frances A. (eds). Treatment of schizophrenia 1999. The expert consensus guideline series // J. Clin. Psychiatry. - 1999. - Vol. 60, Suppl. 11. - P. 3-80.
17. Roth B.L., Sheffler D., Potkin S.J. Atypical antipsychotic drug actions: Unitary or multiple mechanisms for “atypicality” // Clin. Neurosci. Research. - 2003. - Vol. 3. - P. 107-117.
18. Stahl S.M. Essential psychopharmacology: neuroscientific basis and practical application, 4th ed. - Cambridge University Press. - 2013. - 1316 p.
19. Sweileh W.M., Odeh J.B., Shraim N.Y. et al. Evaluation of Defined Daily Dose, percentage of British National Formulary maximum and chlorpromazine equivalents in antipsychotic drug utilization // Saudi Pharm. J. - 2014. - Vol. 22. - P. 127-132.
20. Von Bohlen und Halbach O., Dermietzel R. Neurotransmitters and Neuromodulators: Handbook of Receptors and Biological Effects. - Wiley. - 2006. - 399 p.
21. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics // J. Clin. Psychiatry. - 2003. - Vol. 64. - P. 663-667.
Review
For citations:
Popov M.Yu., Kozlovskaya P.V. Is the «equivalent chlorpromazine» dose in psychopharmacotherapy consistent with Good Clinical Practice? V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY. 2016;(2):15-20. (In Russ.)
Views:
528
Email this article 